Mumbai, August 29 (TNA) The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s C&F unit in Pune after an inspection found that the packaging of Reactin Plus Tablets carried an unauthorised claim.
During the June inspection at the company’s Wadki warehouse, officials said the Schedule H prescription medicine was labelled with the words “analgesic and antipyretic” without approval, constituting misbranding.
The FDA said such promotional claims on a prescription drug violate the Drugs and Cosmetics Act, 1940, and the Rules, 1945. Following the findings, the regulator seized stock valued at around Rs 11.19 lakh and ordered the company to recall the drug from the market.
The cancellation took effect on August 27, 2026, after the FDA found the company’s response to a show-cause notice unsatisfactory.